American Century Investments Focused Dynamic Growth Fund I Class (ACFSX)

NASDAQ · Mutual Fund · Delayed Price · Currency is USD
72.03
+0.66 (0.92%)
Dec 20, 2024, 4:00 PM EST
46.02%
Fund Assets 1.88B
Expense Ratio 0.66%
Min. Investment $5,000,000
Turnover 8.00%
Dividend (ttm) n/a
Dividend Yield n/a
Dividend Growth n/a
Payout Frequency n/a
Ex-Dividend Date n/a
Previous Close 71.37
YTD Return 44.51%
1-Year Return 44.27%
5-Year Return 134.58%
52-Week Low 47.51
52-Week High 74.36
Beta (5Y) n/a
Holdings 42
Inception Date May 31, 2006

About ACFSX

The portfolio managers look for stocks of early and rapid stage growth companies they believe will increase in value over time. The portfolio managers make their investment decisions based primarily on their analysis of individual companies, rather than on broad economic forecasts. The portfolio managers use a variety of analytical research tools and techniques to identify the stocks of companies that meet their investment criteria. Under normal market conditions, the portfolio managers seek securities of companies whose earnings or revenues are not only growing, but growing at an accelerated pace.

Fund Family American Century Investments
Category Large Growth
Performance Rating Average
Risk Rating High
Stock Exchange NASDAQ
Ticker Symbol ACFSX
Index Russell 1000 Growth TR

Performance

ACFSX had a total return of 44.27% in the past year. Since the fund's inception, the average annual return has been 12.27%, including dividends.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol Share Class Expense Ratio
ACFGX G Class 0.01%
ACFNX R6 Class 0.51%
ACFOX Investor Class 0.86%
ACFDX A Class 1.11%

Top 10 Holdings

66.17% of assets
Name Symbol Weight
NVIDIA Corporation NVDA 16.01%
Alphabet Inc. GOOG 11.32%
Amazon.com, Inc. AMZN 10.45%
Tesla, Inc. TSLA 6.70%
Microsoft Corporation MSFT 5.32%
Netflix, Inc. NFLX 3.67%
Salesforce, Inc. CRM 3.46%
Chipotle Mexican Grill, Inc. CMG 3.16%
Alnylam Pharmaceuticals, Inc. ALNY 3.04%
Regeneron Pharmaceuticals, Inc. REGN 3.04%
View More Holdings